Published in Ann Transl Med on October 01, 2016
A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477 | NCT02870400
A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet (2006) 7.05
Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med (2010) 4.88
Characterization of type I receptors for transforming growth factor-beta and activin. Science (1994) 2.94
Different phenotypes for mice deficient in either activins or activin receptor type II. Nature (1995) 2.62
ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med (2015) 1.72
The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci U S A (1996) 1.56
Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J Biol Chem (2012) 1.43
Molecular basis of bone morphogenetic protein-15 signaling in granulosa cells. J Biol Chem (2002) 1.38
A new class of small molecule inhibitor of BMP signaling. PLoS One (2013) 1.36
Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting. Gene Ther (2011) 1.28
Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res (2009) 1.21
An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. J Bone Miner Res (2012) 1.17
The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine Growth Factor Rev (2013) 0.99
Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol (2013) 0.99
Activins and inhibins and their signaling. Ann N Y Acad Sci (2004) 0.98
BMP signalling in skeletal development, disease and repair. Nat Rev Endocrinol (2016) 0.97
Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc Natl Acad Sci U S A (2015) 0.96
Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy. Mol Ther (2014) 0.91
Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding. J Biol Chem (2016) 0.87
A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis. Angiogenesis (2015) 0.84
Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva. PLoS One (2013) 0.84
The role of the 3'UTR region in the regulation of the ACVR1/Alk-2 gene expression. PLoS One (2012) 0.79
The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling. Stem Cell Res Ther (2016) 0.79
The Diversity of the Clinical Phenotypes in Patients With Fibrodysplasia Ossificans Progressiva. J Clin Med Res (2016) 0.77